US10350165B2 – July 16, 2019 – Methods and systems for forming stable droplets

Please complete the required fields.




Inventors :

William Kleidon; Justin Kirkland

Owner :

OJAI ENERGETICS PBC, CALIFORNIA

Application Number :

US16104630

Document Number :

US10350165B2

Priority Date :

August 17, 2018

Filing Date :

August 17, 2018

Date of Grant/ Publication :

July 16, 2019

Class :

A23L2 / 39; A61K31 / 05; A61K31 / 57; A61K47 / 10; A61K47 / 26; A61K47 / 36; A61K47 / 44; A61K47 / 46; A61K9 / 107; A23L33 / 105; A61K31 / 192

Abstract

The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.

Claim(s)

1. A method for generating a plurality of droplets as part of an emulsion, comprising: (a) in a droplet generator, (i) flowing an oil phase comprising one or more compositions present in an amount of at least one microgram along a first channel and (ii) flowing an aqueous phase along a second channel, towards a droplet generation junction of said first channel and said second channel; (b) at said droplet generation junction, bringing said aqueous phase in contact with said oil phase and a surfactant, to generate said emulsion comprising a plurality of droplets, wherein a droplet of said plurality of droplets comprises said one or more compositions from said oil phase, and wherein said droplet has a size less than or equal to about 1 micrometer, wherein said droplet is characterized by one or more members selected from the group consisting of (i) a sigmoidal release profile of said one or more compositions, (ii) a plasma half-life of said one or more compositions greater than twice that of said one or more compositions in non-encapsulated form, (iii) a first pass metabolism of said one or more compositions reduced by at least 50% compared to said one or more compositions in non-encapsulated form, (iv) a rate of excretion of said one or more compositions from a subject’s body reduced by at least 20% compared to said one or more compositions in non-encapsulated form, and (v) a degradation rate at an ambient temperature of at least 20° Celsius (° C.) of said one or more compositions of less than about 50% of a degradation rate of said one or more compositions in non-encapsulated form; and (c) collecting said plurality of droplets.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login